Results 11 to 20 of about 5,684 (155)

Tafamidis Drug Delivery Systems Based on Chitosan/Polyvinyl Alcohol Matrix

Engineering Proceedings, 2023
Cardiovascular diseases retain their position as the leading cause of death globally, and according to the World Health Organization, there are 17.9 million cases of these diseases each year.
Petr Snetkov, Yuliya Generalova, Thi Hong Nhung Vu, Svetlana Morozkina, Mayya Uspenskaya   +4 more
doaj   +2 more sources

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Scientific Reports
Tafamidis is the world's first and only oral drug approved to treat the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM). Medicines are known to have different adverse reactions during the course of treatment.
Fan Wu, He Zhu, Yue Zhang
doaj   +2 more sources

Survival Outcomes in Transthyretin Cardiac Amyloidosis in the Tafamidis Era: Real-World Evidence from Greece [PDF]

Diagnostics
Background: Diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM) have increased in recent years, with a growing proportion of patients being identified at earlier disease stages.
Freideriki Eleni Kourti, Alexios S. Antonopoulos, Vasileios Kytinos, Theodoros Tsampras, Alexandrina Kouroutzoglou, Dimitrios Kyriakopoulos, Maria Eleni Koilakou, Pinelopi Karampina, Vasiliki Gardikioti, Dimitrios Terentes-Printzios, Alexandros Kasiakogias, Ioannis Leontsinis, Christina Chrysohoou, Maria Koutelou, Konstantinos Toutouzas, Konstantinos Tsioufis, Charalambos Vlachopoulos   +16 more
doaj   +2 more sources

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure
Aims Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) in the post‐approval era of tafamidis 61 mg are lacking.
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
doaj   +2 more sources

Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis

Annals of Clinical and Translational Neurology
Objectives Hereditary transthyretin (TTR) amyloidosis (ATTRv) is frequently complicated by polyneuropathy (ATTRv‐PN) and cardiomyopathy (ATTRv‐CM).
Chi‐Chao Chao, Shiou‐Ru Tzeng, Ming‐Chang Chiang, Hsueh‐Wen Hsueh, Wan‐Jen Hsieh, Yuan‐Chun Chao, Mei‐Fang Cheng, Yen‐Hung Lin, Mao‐Yuan Su, Chun‐Hsiang Huang, Yi‐Shiang Wang, Ming‐Fang Hsieh, Ping‐Huei Tseng, Sung‐Tsang Hsieh   +13 more
doaj   +2 more sources

Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy

Cardiology and Therapy
Introduction Tafamidis is approved in many countries for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Approval is largely based on findings from an international phase 3 trial.
Zhuang Tian, Daoquan Peng, Wei Ma, Jiangtao Yan, Jian’an Wang, Yida Tang, Wei Jin, Ying Liu, Caiping Jia, Yingxu Gao, Yankun Gong, Xiaohong Sun, Naihan Chen, Shuiqing Zhu, Shuyang Zhang   +14 more
doaj   +2 more sources

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

Clinical Medicine Insights: Cardiology, 2017
Background: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart.
Marla B Sultan, Balarama Gundapaneni, Jennifer Schumacher, Jeffrey H Schwartz   +3 more
doaj   +2 more sources

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy [PDF]

, 2021
BACKGROUND: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in ...
Sultan, MB, Hoffman, JE, Hummel, SL, Gundapaneni, B, Elliott, P, Lenihan, DJ, Ebede, B, Shah, SJ, Drachman, BM, Gottlieb, SS, Li, B   +10 more
core   +2 more sources

Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms [PDF]

, 2023
AIM: The value of disease-modifying treatment (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and severe heart failure symptoms has been debated.
Elliott, Perry, Ines, Monica, Gundapaneni, Balarama, Garcia-Pavia, Pablo, Sultan, Marla B   +4 more
core   +5 more sources

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysisResearch in context

EClinicalMedicine, 2023
Summary: Background: Previous studies have reported that tafamidis treatment was associated with better outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with those without tafamidis treatment.
Jie Wang, Hongyu Chen, Zihuan Tang, Jinquan Zhang, Yuanwei Xu, Ke Wan, Kifah Hussain, Georgios V. Gkoutos, Yuchi Han, Yucheng Chen   +9 more
doaj   +1 more source